Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease.
Ramon L VarcoeBrian G DeRubertisRaghu KolluriPrakash KrishnanDavid C MetzgerMarc P BonacaMehdi H ShishehborAndrew H HoldenDanielle R BajakianLawrence A GarciaSteven W C KumJohn RundbackEhrin ArmstrongJen-Kuang LeeYazan KhatibIdo WeinbergHector M Garcia-GarciaKarine RusterNutte T TeraphongphomYan ZhengJin WangJennifer M Jones-McMeansSahil A Parikhnull nullPublished in: The New England journal of medicine (2023)
Among patients with CLTI due to infrapopliteal artery disease, the use of an everolimus-eluting resorbable scaffold was superior to angioplasty with respect to the primary efficacy end point. (Funded by Abbott; LIFE-BTK ClinicalTrials.gov number, NCT04227899.).
Keyphrases